AFT Pharmaceuticals Limited (NZE:AFT)

Market Cap	283.14M
Revenue (ttm)	208.02M
Net Income (ttm)	11.96M
Shares Out	104.87M
EPS (ttm)	0.11
PE Ratio	24.55
Forward PE	17.34
Dividend	0.02 (0.67%)
Ex-Dividend Date	Jun 18, 2025

Volume	7,117
Average Volume	13,540
Open	2.650
Previous Close	2.600
Day's Range	2.650 - 2.700
52-Week Range	2.370 - 3.420
Beta	0.31
RSI	54.09
Earnings Date	Aug 21, 2025

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, dermatology, and hospital. It has a research and development collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injecta...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 119
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: AFT

Financial Performance

In 2024, AFT Pharmaceuticals's revenue was 208.02 million, an increase of 6.45% compared to the previous year's 195.41 million. Earnings were 11.96 million, a decrease of -23.36%.